Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Mansoor Husain1*, Agostino Consoli2, Alessandra De Remigis3, Anna Sina Pettersson Meyer3, Søren Rasmussen3 and Stephen Bain4

Abstract

Background: Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to baseline metformin use.

Methods: A post hoc analysis was conducted using pooled SUSTAIN 6 and PIONEER 6 CVOT data in subjects with and without metformin use at baseline. Additionally, a trial-level meta-analysis was conducted using data from seven CVOTs with GLP-1RAs—SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER, REWIND, EXSCEL and AMPLITUDE-O—including adults with type 2 diabetes at high CV risk, and a primary endpoint of time to first major adverse CV event (MACE).

Results: In the post hoc analysis, the no-metformin subgroup was older, with a higher body mass index, lower estimated glomerular filtration rate and higher CV risk at baseline vs the metformin subgroup. Hazard ratios (95% confidence intervals) for the reduction in risk of MACE with semaglutide vs placebo in the metformin and no-metformin subgroups were 0.70 (0.55;0.89) and 0.86 (0.60;1.22), respectively. No significant interaction between the treatment effect on MACE and metformin subgroup was observed. Findings for other CV endpoints were similar. In the meta-analysis, treatment effect (GLP-1RA vs placebo) on CV outcomes was no different with vs without baseline metformin (overall ratio between the hazard ratios for metformin vs no-metformin 1.09 [0.96;1.22]).

Conclusion: These findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs.

Trial registration SUSTAIN 6 (NCT01720446), PIONEER 6 (NCT02692716).

Keywords: Semaglutide, SUSTAIN 6, PIONEER 6, Major adverse cardiovascular event, Cardiovascular outcome trial, Metformin
findings of such CVOTs, management guidelines have been updated to recommend the use of GLP-1RAs and SGLT-2is with proven CV benefits as first-line therapies in people with type 2 diabetes at high or very high risk of, or with atherosclerotic CV disease [8, 9]. However, because the CVOTs were conducted on a background of standard of care [2–7], the majority of trial participants were receiving concomitant metformin. This raises the question of whether the CV benefits of GLP-1RAs and SGLT-2is are contingent on background metformin use, or whether they are also observed in patients not receiving metformin; the question is salient given that guideline updates from the European Society of Cardiology/European Association for the Study of Diabetes and the American Diabetes Association recommend these therapies as first-line agents in the treatment of drug-naïve patients with type 2 diabetes and high or very high risk of a CV event [8, 9]. Recent post hoc and exploratory subgroup analyses of trials with the GLP-1RAs liraglutide and dulaglutide and the SGLT-2is empagliflozin and dapagliflozin have examined this and have suggested that the CV benefits of these agents are observed independent of background metformin use [10–13]. Furthermore, the use of metformin and the CV effects of glucose-lowering agents, including some GLP-1RAs (liraglutide and albiglutide), SGLT-2is and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been investigated in meta-analyses, which have shown no evidence that metformin use at baseline modified the CV effects of GLP-1RAs or SGLT-2is [14, 15].

As semaglutide is a GLP-1RA with proven CV benefits, the aim of this post hoc analysis was to determine whether its effect on CV events varies according to metformin use. To make as robust an examination as possible, the analysis was conducted using data from both SUSTAIN 6 [4] and PIONEER 6 [16], which were preapproval CVOTs of subcutaneous and oral semaglutide, respectively, and which had similar designs and subject populations. Additionally, a comprehensive meta-analysis of published GLP-1RA CVOTs with subgroup data available was conducted. The aim of the analysis was to establish the effect of metformin use at baseline on the CV effects of GLP-1RAs as a drug class.

Methods

Trial designs

The trial designs for SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER, REWIND, EXSCEL and AMPLITUDE-O have been reported previously [2–5, 16–18]. In brief, adults with type 2 diabetes at high risk of a CV event were randomized to a GLP-1RA or placebo in addition to standard of care. The primary endpoint in all trials was time to first major adverse CV event (MACE; a composite of CV death, non-fatal myocardial infarction [MI] or non-fatal stroke). GLP-1RAs by trial were as follows: SUSTAIN 6, semaglutide (once-weekly, subcutaneous); PIONEER 6, semaglutide (daily, oral); HARMONY OUTCOMES, albiglutide (once-weekly, subcutaneous); LEADER, liraglutide (daily, subcutaneous); REWIND, dulaglutide (once-weekly, subcutaneous); EXSCEL, exenatide (once-weekly, subcutaneous); AMPLITUDE-O, epeglenatide (once-weekly, subcutaneous). All trials were approved by Independent Ethics Committees and Institutional Review Boards at each participating center and conducted in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. All subjects provided written informed consent before any trial-related activities.

Subgroups, CV risk score and outcomes

In the post hoc analysis of two subgroups (subjects with metformin use and subjects without metformin use at baseline [metformin/no-metformin]), patient-level data from the SUSTAIN 6 and PIONEER 6 trials were pooled: semaglutide (subcutaneous and oral) vs placebo. A CV risk score for each metformin subgroup was calculated based on a previously published CV risk model [19]. In this model, low scores indicate lower baseline CV risk and, vice versa, high scores indicate higher CV risk.

Event adjudication committee-confirmed CV outcomes were assessed in the two metformin subgroups: time to first MACE (composite of three-components: CV death, non-fatal MI or non-fatal stroke)—the primary outcome; time to first expanded MACE (included CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina or heart failure and, for SUSTAIN 6 only, revascularization [coronary or peripheral]); death from CV or all causes; time to first hospitalization for heart failure (HHF).

The metabolic outcomes assessed by subgroup were change in glycated hemoglobin (HbA1c) and body weight from baseline to week 80 for SUSTAIN 6 and week 83 for PIONEER 6. The safety outcomes assessed by subgroup were investigator-reported serious adverse events (AEs) and patient-reported severe hypoglycemic episodes.

The use of metformin and CV effects of glucose-lowering agents have been investigated in two recently published meta-analyses; however, these two meta-analyses only included two and four GLP-1RAs, respectively [14, 15]. The patient-level and trial-level meta-analysis conducted here includes data from seven CVOTs with GLP-1RAs: SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER, REWIND, EXSCEL and AMPLITUDE-O (data required were not reported for ELIXA). Conducted by trial, data from each of the seven trials
were stratified into two subgroups, subjects receiving metformin at baseline and subjects with no metformin at baseline (metformin/no-metformin), to evaluate the differences in treatment effect on CV outcomes according to baseline metformin use.

**Statistical analysis**

Hazard ratios (HRs; semaglutide:placebo) and 95% confidence intervals (CIs) for CV outcomes were estimated using a Cox proportional hazards model with treatment by metformin subgroup as a fixed factors, stratified by trial (SUSTAIN 6/PIONEER 6) and CV risk at screening (established CV disease and/or chronic kidney disease, or CV risk factors only) (unadjusted analysis). An adjusted analysis was then performed using this model by inclusion of CV–renal risk factors at baseline. Consistency of the treatment effect across the subgroups was assessed using interaction P-values, which indicate whether the average treatment effect in a subgroup is significantly different from that in another subgroup, with $P_{\text{interaction}} < 0.05$ indicating a statistically significant difference. No adjustment for multiplicity was performed.

To assess the impact of post-randomization changes in metformin use, two sensitivity analyses were conducted for the CV outcomes: (1) censoring for initiation and discontinuation of metformin during the study using the Cox proportional hazards model described above; (2) time-dependent Cox regression with metformin use during trial as a time-dependent variable.

A subgroup analysis using inverse probability weighting was also performed based on a Cox proportional hazards model with treatment (semaglutide, placebo), subgroup and treatment by subgroup interaction as fixed factors, stratified by trial (SUSTAIN 6/PIONEER 6) [20]. Weights were 1/non-stabilized propensity scores (probability) of treatment, derived from logistic regressions for each trial separately with subgroup, baseline covariates and subgroup by baseline covariate interactions. Baseline covariates used were: age, sex, prior cardiovascular event, prior heart failure, diabetes duration, HbA1c, estimated glomerular filtration rate (eGFR), weight, body mass index (BMI), diastolic blood pressure, systolic blood pressure, heart rate, low-density lipoprotein (LDL) cholesterol, insulin use, thiazolidinedione use, sulfonylurea use, angiotensin-converting-enzyme inhibitor (ACEi) use, angiotensin II receptor blocker use and statin use.

For change in the metabolic outcomes from baseline to week 80 (SUSTAIN 6)/83 (PIONEER 6), analyses were based on a mixed model for repeated measurements, with treatment by metformin subgroup adjusted for baseline value and trial nested within visits. For the safety analyses, number of events per 100 patient-years were analyzed using a negative binomial regression model with a log link and the logarithm of the observation time (100 years) as offset, with treatment by metformin subgroup as fixed factors adjusted by trial.

All analyses were performed using observed in-trial data from the full analysis set; data used for all analyses (except for the meta-analysis) were patient-level. For CV risk at screening, the P-value for the difference between groups was estimated using a Wilcoxon test. For the meta-analysis (which used both patient-level and trial-level data), HRs (active comparator: placebo) and 95% CIs for CV outcomes were estimated using a Cox proportional hazards model. In the meta-analysis, HRs from the individual trials were pooled according to metformin use at baseline using the fixed- and random-effect method. The HRs were obtained from published papers, except for SUSTAIN 6 and PIONEER 6, for which patient-level data were used. The fixed-effect model assumed all trials were estimating a common treatment effect; the random-effect model assumed that the underlying treatment effect could vary across trials [21].

**Results**

**Baseline characteristics**

SUSTAIN 6 and PIONEER 6 included 6,480 subjects, of whom 4,881 (75%) were receiving metformin at baseline. There were notable differences in some baseline characteristics between the subgroups (Table 1). Compared with subjects receiving metformin at baseline, those not receiving metformin at baseline were older (mean [standard deviation (SD)]: 67.1 [7.9] vs 64.8 [7.0] years of age), with higher BMI (33.2 [7.0] vs 32.3 [6.1] kg/m²) and lower eGFR (61.9 vs 79.4 mL/min/1.73 m²). The no-metformin subgroup also had a higher proportion of subjects with concomitant insulin use (70.7% vs 48.2%) and a lower proportion of subjects with concomitant sulfonylurea use (28.7% vs 40.5%). Additionally, compared with subjects receiving metformin at baseline, the subgroup not receiving metformin had a higher CV risk score at screening (−0.7 [0.6] and −1.0 [0.5], respectively; $P<0.0001$) (Fig. 1).

**CV outcomes and all-cause mortality**

The HRs (95% CIs) for the reduction in risk of three-component MACE (primary endpoint) with semaglutide vs placebo in the metformin and no-metformin subgroups were 0.70 (0.55;0.89) and 0.86 (0.60;1.22), respectively, in the adjusted analysis (Fig. 2). There was no significant interaction between the treatment effect (semaglutide vs placebo) on MACE and subgroup (metformin, yes/no) ($P_{\text{interaction}}$ not significant). Findings for expanded MACE were similar, both within each subgroup for semaglutide vs placebo and for interaction analyses between the two subgroups (Fig. 2). The results
Table 1 Baseline characteristics by metformin use subgroup, based on pooled SUSTAIN 6 and PIONEER 6 data

| Metformin | No-metformin | P-value |
|-----------|--------------|---------|
| Randomized, N (%) | 488 | 1599 | |
| Age, years | 64.8 (7.0) | 67.1 (7.9) | <0.0001 |
| Female, n (%) | 1718 (35.2) | 584 (36.5) | 0.3366 |
| Prior cardiovascular event, n (%) | 2190 (44.9) | 694 (43.4) | 0.3060 |
| Prior heart failure, n (%) | 852 (17.5) | 313 (19.6) | 0.0555 |
| Diabetes duration, years | 13.8 (8.0) | 16.0 (9.2) | <0.0001 |
| HbA1c, % | 8.4 (1.5) | 8.6 (1.6) | <0.0001 |
| HbA1c, mmol/mol | 68.1 (16.8) | 70.5 (17.6) | <0.0001 |
| eGFR, mL/min/1.73 m² | 79.4 (19.5) | 61.9 (23.8) | <0.0001 |
| eGFR < 60 mL/min/1.73 m², n (%) | 880 (18.0) | 519 (32.1) | <0.0001 |
| Albuminuria, n (%) | 855 (36.0) | 449 (31.9) | N/A |
| Concomitant insulin use, n (%) | 2351 (48.2) | 1130 (70.7) | <0.0001 |
| TZD use, n (%) | 129 (2.6) | 65 (4.1) | <0.0001 |
| Sulfonylurea, n (%) | 1978 (40.5) | 459 (28.7) | <0.0001 |
| DPP-4i, n (%) | 5 (0.1) | 2 (0.1) | | |
| Body weight, kg | 90.8 (20.3) | 93.6 (22.5) | 0.0002 |
| BMI, kg/m² | 32.3 (6.1) | 33.2 (7.0) | 0.0004 |
| Diastolic BP, mmHg | 76.8 (9.9) | 75.7 (10.4) | <0.0001 |
| Systolic BP, mmHg | 135.4 (17.1) | 136.2 (18.2) | 0.1289 |
| Heart rate, bpm | 71.8 (11.2) | 70.7 (10.9) | 0.0015 |
| LDL-cholesterol, mmol/L | 2.2 (0.9) | 2.4 (0.9) | <0.0001 |
| LDL-cholesterol, mg/dL | 85.6 (35.2) | 91.7 (36.1) | <0.0001 |
| ACEis, n (%) | 2304 (47.2) | 680 (42.5) | 0.3541 |
| ARBs, n (%) | 1800 (36.9) | 570 (35.6) | 0.3541 |
| Statin, n (%) | 3798 (77.8) | 1200 (75.0) | 0.0229 |

Data are mean (SD) unless stated otherwise

*Albuminuria percentage is calculated based on number of subjects with a urinary albumin-to-creatinine ratio measurement at baseline (only available for SUSTAIN 6).

b P-value for interaction between different blood glucose-lowering medication, which included TZDs and other classes of medications.

c P-value for interaction between different anti-hypertensive therapy, which included ACEis, ARBs and other classes of medications.

d P-value for interaction between different lipid-lowering medications, which included statins and other classes of medications.

ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blockier, BMI body mass index, BP blood pressure, DPP-4 dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, LDL low-density lipoprotein, N/A not available, SD standard deviation, TZD thiazolidinedione

of the unadjusted analyses were similar to the adjusted analyses (Additional file 1: Fig. S1). Additionally, there was no significant reduction in the HR for CV death, all-cause mortality or HHF in either metformin subgroup and no significant interaction between the treatment effect (semaglutide vs placebo) on these outcomes and subgroup (metformin, yes/no) (Pinteraction not significant for either outcome). Both sensitivity analyses and CV outcomes by trial supported the findings of the main analysis (Additional file 1: Figs. S2–5). The results of the propensity analysis also supported the main analysis (Additional file 1: Fig. S6).

Metabolic outcomes
Semaglutide reduced HbA1c and body weight compared with placebo regardless of baseline metformin use (Fig. 3). No significant differences in change from baseline in HbA1c or body weight were observed between the two subgroups (Pinteraction: 0.42 and 0.51, respectively).

Safety
Within each metformin subgroup, the proportions of subjects experiencing either an investigator-reported serious AE or a patient-reported severe hypoglycemic episode with semaglutide and placebo were comparable. Cardiac disorder events classified in the system organ class were experienced by 8.5% and 9.9% of subjects in the metformin at baseline subgroup receiving semaglutide and placebo, respectively, and by 11.7% and 12.7% of subjects in the subgroup not receiving metformin. Gastrointestinal disorders were experienced by 2.8% and 1.9% in the metformin, and 4.5% and 3.4% of subjects in the no-metformin subgroup receiving semaglutide and placebo, respectively.

With both semaglutide and placebo, the proportion of subjects experiencing serious AEs was higher in those without metformin use at baseline compared with those receiving metformin at baseline: 279/805 (34.7%) and 303/794 (38.2%) without metformin with semaglutide and placebo, respectively, and 610/2,434 (25.1%) and 695/2,447 (28.4%) with metformin. Similarly, a higher proportion of subjects experienced severe hypoglycemic episodes in the no-metformin subgroup compared with the metformin subgroup: 18/805 (2.2%) and 20/794 (2.5%) in no-metformin patients with semaglutide and placebo, respectively, and 33/2,434 (1.4%) and 25/2,447 (1.0%) in the metformin at baseline patients. The estimated treatment differences/estimated risk ratios are shown in Fig. 3 for metabolic and safety outcomes, respectively.

Meta-analysis
Across seven of the CVOTs—SUSTAIN 6, PIONEER 6, HARMONY OUTCOMES, LEADER,REWIND, EXSCEL and AMPLITUDE-O—treatment effect on CV outcomes (GLP-1RA vs placebo) was no different in subjects with or without metformin at baseline (Fig. 4). Although the effect on MACE with and without metformin trended in different directions comparing the ratio of the HR in the different CVOTs, there was no statistical evidence
to suggest that baseline metformin use modified the CV effect of any of the GLP-1RAs (Fig. 4). The random-effect estimated ratio between the HRs for metformin vs no-metformin groups was similar (1.09 [0.96;1.22], \(P = 0.3921\)), and inconsistency across the estimates was 0 (I\(^2\)), suggesting no heterogeneity was observed between trials. Similar results were also obtained using a fixed-effect model.

**Discussion**

This analysis indicates that semaglutide provides CV benefits regardless of baseline metformin use, as there was no significant interaction between the semaglutide treatment effect and metformin use at baseline. This finding was consistent across the unadjusted and adjusted analysis and was supported by both sensitivity analyses and the propensity analysis.

For metabolic outcomes, there was homogeneity in the treatment differences across the metformin subgroups. More serious AEs and severe hypoglycemic episodes were observed in subjects not receiving metformin than in those receiving metformin at baseline. One hypothesis that may explain the safety findings in this analysis is that metformin tends to be discontinued in more frail individuals, such as the elderly and those with decreased kidney function [22]. In these CVOTs, patients without metformin use at baseline may represent a frailer subgroup, who are at greater risk of serious AEs, than the metformin subgroup. Clinically meaningful differences in their baseline characteristics support this hypothesis, as does the externally derived CV risk score.

Compared with the metformin subgroup, those without metformin at baseline were also more likely to be receiving concomitant insulin at baseline, which may help to explain the increased proportion of subjects in the no-metformin subgroup who experienced a severe hypoglycemic episode. The no-metformin subgroup may also have been at increased risk of hypoglycemia, as subjects in this group were older and with a lower eGFR. Although the risk of hypoglycemia with GLP-1RAs is low due to their glucose-dependent mechanism of action [23], when used in combination with other drugs the risk of hypoglycemia may increase. Indeed, lowering the dose of insulin or sulfonylurea can reduce this risk when initiating treatment with semaglutide [24].

The meta-analysis showed that metformin use did not modify the CV effects in any of the trials analyzed. These results support the findings of two similar meta-analyses that looked at the effect of baseline metformin use in the HARMONY-OUTCOMES and LEADER trials, and the HARMONY-OUTCOMES, REWIND, EXSCEL and LEADER trials, respectively [14, 15], as well as individual analyses investigating the impact of baseline metformin use on CV risk in patients treated with different GLP-1RAs reported previously [10–12]. This includes the recently reported AMPLITUDE-O analyses, which suggested that the CV benefits seen with efpeglenatide were independent of baseline metformin use [17]. The results are also supported by a meta-analysis considering only data from subjects not receiving metformin at baseline in the HARMONY-OUTCOMES and LEADER trials,
Fig. 2  A CV outcomes/mortality by baseline metformin use (adjusted analysis); B Kaplan–Meier curves of primary outcome by baseline metformin. Figures (A) and (B) compare semaglutide with placebo. *n-numbers are based on the FAS; the number of subjects included for each endpoint analysis differed according to data availability. A Analyses for SUSTAIN 6 and PIONEER 6 are based on a Cox proportional hazards model with treatment (semaglutide, placebo) by metformin subgroup as fixed factors, stratified by trial and CV risk group (established CVD and/or CKD vs risk factors), and adjusted by baseline variables: sex (male vs female), smoker (current smoker, previous smoker, never smoked), previous MI/stroke/TIA (yes vs no), region (European Union, North America, other), antidiabetic treatment (yes vs no), diabetes duration, eGFR-MDRD and age. CI confidence interval, CKD chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, eGFR-MDRD estimated glomerular filtration rate-modification of diet in renal disease, FAS full analysis set, HbA1c glycated hemoglobin, HHF hospitalization for heart failure, HR hazard ratio (semaglutide vs placebo), MACE major adverse cardiovascular event, MET metformin, MI myocardial infarction, TIA transient ischemic attack.
which found that GLP-1RAs are effective at reducing CV risk in metformin-naïve subjects [25].

While a full discussion of the mechanisms behind GLP-1RA-mediated CV risk reduction is beyond the scope of this article, we note that the interaction P-values suggest no difference in the treatment effect on CV outcomes when semaglutide is used with or without metformin. This finding indicates that, while glycemic control may play a role in CV risk reduction, it is not the only mechanism involved. This is in line with previous findings with semaglutide and other GLP-1RAs [26].

Limitations of both the analysis reported here and previous meta-analyses are that the trials they include were not specifically designed to address these research questions, and that the trials included subjects at high risk of a CV event and, as such, may not be representative of the broader type 2 diabetes population. Additionally, one impetus for this analysis was the updates to guidelines stating that GLP-1RAs can be used as first-line therapy in patients with type 2 diabetes and high CV risk [8, 9]. First-line therapy indicates use in treatment-naïve patients; however, the no-metformin subgroup is not precisely representative of such a population. Also, there are limitations inherent to any post hoc (vs prospective) analyses of randomized clinical trials. A further limitation of the present post hoc analysis of SUSTAIN 6 and PIONEER 6 is that the number of CV events was low, and the trial durations were shorter than for other CVOTs; therefore, exposure to study drug was limited. There were also fewer subjects in the no-metformin subgroup compared with the metformin subgroup, and the interaction results
have limited statistical power; furthermore, the test for interaction did not indicate the direction of the treatment effect. Additionally, although an adjusted analysis was conducted, not all factors may have been accounted for. Urinary albumin-creatinine ratio was, for instance, not included as these data were not available from PIO-
NEER 6. However, a subgroup analysis using inverse probability weighting including a wider range of covariates was conducted, and the findings of this analysis were aligned with those of the main analysis. The possible effect of other glucose-lowering medications was also not analyzed. The trials included in the meta-analysis had different durations; subject characteristics may also have differed between trials and between the subgroups with and without metformin, which could influence the CV effect of different drugs.

Despite these limitations, the data reported here add to the growing body of evidence that the effect of semaglutide on MACE is similar regardless of metformin use at baseline. Our meta-analysis showed that baseline metformin did not modify the CV benefit shown across CVOTs evaluating different GLP-1RA therapies. While, for reasons of cost and access, metformin may be used as first-line therapy in some countries, the data presented here and elsewhere support the use of GLP-1RAs, such as semaglutide, in patients with type 2 diabetes and a high or very high risk of a CV event whether they are receiving metformin or not.

Conclusions
In conclusion, these findings indicate that the CV, metabolic and safety outcomes for semaglutide were similar regardless of metformin use at baseline. These findings may be applicable to all GLP-1RAs, and support the guideline recommendation that GLP-1RAs such as semaglutide should be used in patients with type 2 diabetes and a high or very high risk of CV events [8, 9].

Abbreviations
ACEi: Angiotensin-converting enzyme inhibitor; AE: Adverse event; ARB: Angiotensin receptor blocker; BMI: Body mass index; BP: Blood pressure; CI: Confidence interval; CKD: Chronic kidney disease; CV: Cardiovascular; CVD: Cardiovascular disease; CVOTs: Cardiovascular outcome trials; DPP-4i: Dipepi-
tidy peptide-4 inhibitor; eGFR: Estimated glomerular filtration rate; ERR: Estimated risk ratio; ETD: Estimated treatment difference; FAS: Full analysis set;
Consent for publication
Not applicable.

Competing interests
MH reports receiving research grants from Novo Nordisk, AstraZeneca and Merck; consultancy fees for participation in advisory board meetings from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk and Roche; speaker fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck and Novo Nordisk; payment for expert testimony from Novo Nordisk; and holds one patent relating to GLP-1, and has one patent pending relating to methods for inhibiting platelet aggregation using GLP-1RAs. AC reports receiving clinical research grants from Novo Nordisk; speaker fees from Novo Nordisk; speaker fees from Novo Nordisk, Eli Lilly, AstraZeneca and Sanofi Aventis; and remuneration for participation on data safety monitoring or advisory boards for Novo Nordisk, Eli Lilly and AstraZeneca. ADR, ASPM and SR are all employees of Novo Nordisk, and SR holds stock in the company. SB reports receiving speaker fees from Novo Nordisk; and support for attending meetings and/or travel from the American Diabetes Association and the European Association for the Study of Diabetes meetings.

Author details
1 Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto, Peter Munk Cardiac Centre, Toronto General Hospital, 200 Elizabeth St, PMCRT 3-904, M5G2C4 Toronto, Canada. 2 DMSI & CAST, University G. d’Annunzio, Chieti-Pescara, Italy. 3 Novo Nordisk A/S, Søborg, Denmark. 4 Swansea University Medical School, Swansea, UK.

Acknowledgements
We thank all the participants, investigators, and trial-site staff. We also thank Flavia Sciota, PhD (AXON Communications) for medical writing and editorial assistance (funded by Novo Nordisk A/S).

Author contributions
SR performed statistical analyses. All authors acquired, analyzed, or interpreted data; drafted and critically revised the manuscript. ADR is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All the authors have read and approved the final manuscript.

Funding
SUSTAIN 6, PIONEER 6, and the post hoc and meta-analyses presented in this manuscript were funded by Novo Nordisk A/S.

Availability of data and materials
Will individual participant data be available (including data dictionaries)?: Yes. Individual participant data will be shared in data sets in a de-identified/anonymous format. What data in particular will be shared?: Data sets from Novo Nordisk-sponsored clinical research completed after 2001 for product indications approved in both the EU and USA, What other documents will be available?: The study protocol and redacted Clinical Study Report (CSR) will be available according to Novo Nordisk data sharing commitments; When data will be available (start and end dates): The data will be available permanently after research completion and approval of product and product use in both EU and USA. No end date: With whom will data be shared?: With bona fide researchers submitting a research proposal and requesting access to data; For what types of analyses?: For use as approved by the Independent Review Board (IRB) according to the IRB Charter (see www.novonordisk-trials.com), By what mechanism will data be made available?: The access request proposal and the access criteria can be found at www.novonordisk-trials.com. The data will be made available on a specialized SAS data platform.

Declarations
Ethics approval and consent to participate
All studies were approved by Independent Ethics Committees and Institutional Review Boards at each participating center and conducted in compliance with the International Conference on Harmonisation Good Clinical Practice (GCP) guidelines and Declaration of Helsinki. All subjects provided written informed consent before any trial-related activities.

References
1. Rao Kondapally Sehassai, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sanwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.
2. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1289–33.
3. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
4. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Johs E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
5. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10213):121–30.
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
7. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondo N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
8. Cosentino F, Grant PJ, Abayans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
9. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S125–43.
10. Crowley MJ, McGuire DK, Alexopoulos AS, Jensen T, Rasmussen S, Saeve-reid HA, et al. Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. Diabetes Care. 2020;43(9):e108–10.
11. Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, et al. Similar cardiovascular outcomes in patients with diabetes

GLP-1RA: Glucagon-like peptide-1 receptor agonist; HbA1c: Glycated hemoglobin; HHF: Hospitalization for heart failure; HR: Hazard ratio; I2: Inconsistency across estimates; LDL: Low-density lipoprotein; MACE: Major adverse cardiovascular event; MDRD: Modification of Diet in Renal Disease; MET: Metformin; MI: Myocardial infarction; N/A: Not available; R: Events per 100 patient-years observed; RHR: Ratio between the hazard ratios in metformin vs no-metformin groups; SD: Standard deviation; SGLT2: Sodium–glucose cotransporter-2 inhibitor; TIA: Transient ischemic attack; TZD: Thiazolidinedione.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01489-6.

Additional file 1: Figure S1. CV outcomes by metformin use at baseline (unadjusted analysis). Figure S2. CV outcomes by metformin use at baseline censored for initiation and discontinuation of metformin. Figure S3. CV outcomes by metformin use at baseline adjusted for time-dependent metformin use during trial (yes/no). Figure S4. CV outcomes and all-cause mortality with semaglutide vs placebo by baseline metformin use (SUSTAIN 6). Figure S5. CV outcomes and all-cause mortality with semaglutide vs placebo by baseline metformin use (PIONEER 6). Figure S6. CV outcomes and mortality by baseline metformin use using inverse probability weighting.
and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J. 2020;42:2565–73.

12. Inzucchi SE, Fitchett D, Junisć-Eržen D, Woo V, Hantel S, Janista C, et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes Metab. 2020;22(4):631–9.

13. Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, et al. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021;23(1):29–38.

14. Zaccardi F, Kloecker DE, Buse JB, Mathieu C, Khunti K, Davies MJ. Use of metformin and cardiovascular effects of new classes of glucose-lowering agents: a meta-analysis of cardiovascular outcome trials in type 2 diabetes. Diabetes Care. 2021;44:e32–4.

15. Tsalas A, Karagiannis T, Avgiernos I, Liakos A, Bekiari E. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin: A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract. 2021;177:108921.

16. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Elischewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.

17. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with epeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907.

18. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.

19. Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol. 2020;19(1):156.

20. Iezzi R, Liao J, Hu M, Wei Y, Akhtar S, Wennecke M, et al. Comparison of propensity score methods for pre-specified subgroup analysis with survival data. J Biopharm Stat. 2020;30(4):734–51.

21. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.

22. Schröeder L, Martinez YV, Adeniji C, Reeves D, Faller B, Sommerauer C, et al. Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2017;17(1):227.

23. Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 2020;132(sup1):13–14.

24. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98.

25. Masson W, Laval–Cobo A, Lobo M, Masson G, Molinero G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur J Prev Cardiol. 2021;28(1):69–75.

26. Nauck MA, Meier JJ, Cavender MA, Abd El Azz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.